Fulvestrant STADA Nordic
Fulvestrant – Selective Estrogen Receptor Degrader (SERD) for Hormone Receptor-Positive Breast Cancer
Fulvestrant STADA Nordic is a prescription-only injectable medicine containing the active ingredient fulvestrant, a selective estrogen receptor degrader (SERD). It is used to treat hormone receptor-positive (HR+) locally advanced or metastatic breast cancer in postmenopausal women, either as monotherapy or in combination with targeted agents such as CDK4/6 inhibitors. Fulvestrant works by binding to and degrading estrogen receptors, completely blocking estrogen-driven tumor growth.
Quick Facts
Key Takeaways
- Fulvestrant STADA Nordic is a selective estrogen receptor degrader (SERD) that completely blocks and eliminates estrogen receptor signaling in breast cancer cells, unlike tamoxifen which retains partial estrogen activity.
- It is administered as two intramuscular injections (one in each buttock) every month, with an additional loading dose on day 15 of the first month to rapidly achieve therapeutic levels.
- Fulvestrant is commonly combined with CDK4/6 inhibitors (palbociclib, ribociclib, or abemaciclib) as first-line endocrine therapy for advanced HR+/HER2- breast cancer, significantly improving progression-free survival.
- The most frequent side effects are injection site reactions, nausea, musculoskeletal pain, fatigue, and hot flushes, with most being mild to moderate in severity.
- Treatment is continued for as long as clinical benefit is observed, and women of childbearing potential must use effective contraception during treatment and for 2 years after the last dose.
What Is Fulvestrant STADA Nordic and What Is It Used For?
Fulvestrant STADA Nordic contains the active substance fulvestrant, which belongs to a class of medications known as antiestrogens. More specifically, fulvestrant is classified as a selective estrogen receptor degrader (SERD), representing a distinct mechanism of action compared to other hormonal breast cancer therapies. While selective estrogen receptor modulators (SERMs) like tamoxifen block the estrogen receptor but still allow partial activation in some tissues, fulvestrant binds to the estrogen receptor with high affinity, prevents receptor dimerization, and accelerates the degradation and downregulation of the receptor protein. This results in a complete loss of estrogen receptor signaling, making it effective even in cancers that have developed resistance to other antiestrogen treatments.
Breast cancer is the most commonly diagnosed cancer worldwide, and approximately 70–80% of all breast cancers are hormone receptor-positive, meaning the cancer cells rely on estrogen to grow and multiply. Endocrine (hormonal) therapy forms the backbone of treatment for these cancers, and fulvestrant plays an important role in this treatment paradigm, particularly in the advanced or metastatic setting.
Fulvestrant STADA Nordic is indicated for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer in postmenopausal women who have not previously been treated with endocrine therapy, or in whom disease has progressed on or after prior antiestrogen therapy. It is approved for use as monotherapy and is also widely used in combination with other targeted agents. The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have approved fulvestrant in combination with CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) for the first-line or second-line treatment of HR+/HER2-negative advanced breast cancer. Additionally, fulvestrant is approved in combination with the PI3K inhibitor alpelisib for patients with PIK3CA-mutated, HR+/HER2-negative advanced breast cancer that has progressed after endocrine therapy.
The development of fulvestrant represented a significant advance in breast cancer pharmacotherapy. By providing an option that completely eliminates estrogen receptor signaling rather than merely modulating it, fulvestrant expanded the treatment arsenal for patients with endocrine-resistant disease. Its mechanism of action also makes it a valuable backbone therapy in combination regimens with newer targeted agents, which together have substantially improved progression-free survival outcomes for patients with advanced HR+ breast cancer.
Mechanism of Action
Fulvestrant competitively binds to the estrogen receptor (ER) with an affinity approximately 100 times that of tamoxifen. Upon binding, fulvestrant prevents receptor dimerization, which is essential for the receptor to function as a transcription factor. It also blocks nuclear localization of the receptor and increases receptor turnover through proteasomal degradation. The net effect is a dramatic reduction in cellular estrogen receptor levels, effectively removing the ability of estrogen to stimulate cancer cell proliferation. This mechanism is often described as “pure antiestrogen” activity because, unlike tamoxifen or raloxifene, fulvestrant has no partial agonist effects in any tissue.
In preclinical studies, fulvestrant has been shown to inhibit estrogen-stimulated growth of human breast cancer cell lines, including those that are resistant to tamoxifen. The drug also reduces the expression of progesterone receptor (PgR), which is an estrogen-regulated gene, confirming the complete blockade of estrogen receptor signaling at the molecular level.
What Should You Know Before Taking Fulvestrant STADA Nordic?
Contraindications
Fulvestrant STADA Nordic must not be used in patients with known hypersensitivity to fulvestrant or to any of the excipients contained in the formulation. It is strictly contraindicated during pregnancy and breastfeeding due to potential harm to the developing fetus or nursing infant. Animal studies have demonstrated reproductive toxicity, including increased incidence of fetal abnormalities and pregnancy loss. Women who are or may become pregnant should not receive this medication under any circumstances.
Fulvestrant has not been studied in patients with severe hepatic impairment (Child-Pugh class C), and its use in this population is not recommended. In patients with mild to moderate hepatic impairment, dose adjustments may not be necessary based on pharmacokinetic data, but caution is advised as increased drug exposure has been observed in patients with moderate hepatic impairment.
The safety and efficacy of fulvestrant have not been established in children and adolescents, and it should not be used in the pediatric population. Additionally, fulvestrant has not been evaluated in patients with severe renal impairment (creatinine clearance less than 30 mL/min), and caution is recommended in this group.
Warnings and Precautions
Because fulvestrant is administered as an intramuscular injection, special care should be exercised in patients with bleeding diatheses, thrombocytopenia, or those receiving anticoagulant therapy. The intramuscular route of administration carries an inherent risk of local bleeding, bruising, or hematoma at the injection site, which may be exacerbated in patients with impaired hemostasis.
Thromboembolic events have been reported in patients treated with fulvestrant, although a clear causal relationship has not been definitively established. Patients with a history of thromboembolic disease or those with multiple risk factors for venous thromboembolism should be monitored carefully. The risk-benefit assessment should be carefully considered in these patients.
Liver function should be monitored during treatment with fulvestrant, as elevations in hepatic transaminases (ALT, AST) and bilirubin have been reported. In clinical trials, hepatobiliary disorders including hepatitis and hepatic failure have been reported rarely. If clinically significant liver enzyme elevations occur, treatment discontinuation should be considered.
Pregnancy and Breastfeeding
Fulvestrant is classified as pregnancy category D, meaning there is positive evidence of human fetal risk. Animal reproductive studies using doses lower than the human clinical dose have demonstrated adverse effects including increased pre- and post-implantation loss, increased incidence of fetal abnormalities (including tarsal flexure), and dystocia. Given the mechanism of action of fulvestrant as an antiestrogen, fetal exposure could disrupt normal hormone-dependent developmental processes.
Women of childbearing potential should be counseled about the need for effective contraception before starting treatment and should use reliable methods of birth control during therapy and for at least 2 years after the last injection. This extended period reflects the slow elimination of fulvestrant from the body following intramuscular administration, with an apparent terminal half-life of approximately 40 days.
It is not known whether fulvestrant is excreted in human breast milk. Given the potential for serious adverse effects in nursing infants, breastfeeding is contraindicated during treatment with fulvestrant and for a period after the last dose. A decision should be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the importance of the medicine to the mother.
How Does Fulvestrant STADA Nordic Interact with Other Drugs?
Fulvestrant is primarily metabolized by cytochrome P450 enzyme 3A4 (CYP3A4), with additional contributions from CYP3A5 and other metabolic pathways. Despite this hepatic metabolism, clinical studies have shown that co-administration with CYP3A4 inhibitors does not significantly affect fulvestrant pharmacokinetics to a degree that requires dose adjustment. This is likely because fulvestrant absorption from the intramuscular depot is the rate-limiting step, and the drug has multiple metabolic pathways, limiting the impact of any single enzyme inhibitor.
In a clinical pharmacokinetic study, co-administration of fulvestrant with rifampicin (a potent CYP3A4 inducer) resulted in a modest reduction (approximately 13%) in fulvestrant AUC, which was not considered clinically meaningful. Similarly, co-administration with ketoconazole (a potent CYP3A4 inhibitor) produced no clinically relevant change in fulvestrant pharmacokinetics. These findings suggest that dose adjustments are generally not required when fulvestrant is used alongside common CYP3A4 modulators.
Fulvestrant does not significantly inhibit any of the major CYP450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, or CYP3A4) at clinically relevant concentrations, indicating a low propensity to cause drug interactions through inhibition of other drug metabolism.
Major Interactions
| Drug/Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Anticoagulants (warfarin, heparin, DOACs) | Increased bleeding risk due to IM injection route | Monitor for injection site bleeding; apply pressure post-injection |
| Antiplatelet agents (aspirin, clopidogrel) | Increased bruising/bleeding at injection site | Caution advised; consider timing of injection relative to dosing |
| Estrogen-containing therapies (HRT, oral contraceptives) | Pharmacodynamic antagonism | Contraindicated – would counteract fulvestrant efficacy |
Minor Interactions
| Drug/Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Strong CYP3A4 inhibitors (ketoconazole, itraconazole) | Potential increase in fulvestrant exposure | No dose adjustment required; monitor clinically |
| Strong CYP3A4 inducers (rifampicin, phenytoin, carbamazepine) | Potential decrease in fulvestrant exposure (~13%) | Not clinically significant; no dose adjustment needed |
| CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) | No pharmacokinetic interaction identified | Approved combination – safe to use together |
| Alpelisib (PI3K inhibitor) | No pharmacokinetic interaction identified | Approved combination – safe to use together |
When fulvestrant is used in combination with CDK4/6 inhibitors, no pharmacokinetic interactions have been observed in clinical studies. The combination of fulvestrant with palbociclib, ribociclib, or abemaciclib has been extensively studied in large randomized controlled trials and is well-established in clinical practice. Similarly, the combination with alpelisib has been studied in the SOLAR-1 trial without pharmacokinetic concerns. However, each combination partner has its own side effect profile and interaction potential, which should be reviewed separately.
What Is the Correct Dosage of Fulvestrant STADA Nordic?
Adults
Standard Adult Dosage
The recommended dose for adult postmenopausal women is 500 mg fulvestrant administered intramuscularly. This is given as two separate 5 mL injections (250 mg each), one injection into each buttock (gluteal area). The injections should be administered slowly, over a period of 1–2 minutes per injection site.
Loading schedule: Day 1, Day 15, Day 29, then once monthly (every 28 ± 3 days) thereafter.
The loading dose regimen (with the additional day 15 injection) was developed based on pharmacokinetic modeling demonstrating that achieving adequate drug levels early in treatment leads to better clinical outcomes. The CONFIRM trial established that the 500 mg dose is superior to the previously used 250 mg dose, with significantly improved progression-free survival. The loading dose on day 15 allows plasma concentrations to reach steady-state levels more rapidly, providing therapeutic drug exposure from the outset of treatment.
Fulvestrant must be administered by a healthcare professional experienced in giving intramuscular injections. The injection should be given into the gluteal muscle (buttock), with the needle inserted slowly and steadily. Each injection should be administered into a different buttock. Patients should be advised to remain in the clinic for a brief observation period following injection, particularly during the first few administrations.
Pre/Perimenopausal Women
Pre/Perimenopausal Women
Fulvestrant is not indicated for premenopausal women as monotherapy. However, it may be used in combination with a gonadotropin-releasing hormone (GnRH) agonist (such as goserelin) to achieve ovarian suppression in pre/perimenopausal women with HR+/HER2- advanced breast cancer. The dosage of fulvestrant remains the same (500 mg as per the standard schedule), and the GnRH agonist is administered according to its own prescribing information.
Elderly Patients
Elderly Patients (≥65 years)
No dose adjustment is required for elderly patients. Clinical trials included patients up to 89 years of age, and no overall differences in safety or efficacy were observed between older and younger patients. However, age-related hepatic and renal function decline should be considered, and monitoring for adverse effects may be appropriate.
Hepatic Impairment
Dose Adjustment for Hepatic Impairment
Mild impairment (Child-Pugh A): No dose adjustment required.
Moderate impairment (Child-Pugh B): Reduce dose to 250 mg (one injection) on days 1, 15, 29, then once monthly. AUC is increased approximately 2.5-fold in moderate hepatic impairment.
Severe impairment (Child-Pugh C): Not recommended – fulvestrant has not been studied in this population.
Renal Impairment
No dose adjustment is required for patients with mild to moderate renal impairment (creatinine clearance ≥30 mL/min). Fulvestrant has not been specifically studied in patients with severe renal impairment (creatinine clearance <30 mL/min), and caution should be exercised in this population.
Missed Dose
If a scheduled injection is missed, it should be administered as soon as possible. There is no need to restart the loading regimen if a maintenance dose is delayed. The next injection should then be scheduled approximately one month after the missed dose was given, not from the originally planned date. If a significant delay occurs (more than 2 weeks beyond the scheduled date), consult your oncologist regarding the optimal time to resume treatment.
Overdose
There is no specific antidote for fulvestrant overdose. In the event of overdose, management should be supportive and symptomatic. In clinical trials, single doses of up to 750 mg and multiple doses of up to 750 mg monthly were administered without additional safety concerns beyond those observed at the recommended dose. Given the intramuscular route of administration and the slow-release formulation, accidental overdose is unlikely in clinical practice.
What Are the Side Effects of Fulvestrant STADA Nordic?
Like all medicines, Fulvestrant STADA Nordic can cause side effects, although not everybody gets them. The safety profile of fulvestrant has been characterized in large randomized controlled trials involving thousands of patients. The side effects listed below are categorized by frequency according to the MedDRA convention used by the EMA and other regulatory agencies.
Understanding the frequency categories helps patients and healthcare professionals assess the relative likelihood of experiencing specific side effects. In clinical practice, most patients tolerate fulvestrant well, and the overall safety profile compares favorably to many other oncological treatments, including oral aromatase inhibitors and chemotherapy.
Very Common
Affects more than 1 in 10 patients (>10%)
- Nausea
- Injection site reactions (pain, inflammation, swelling, induration)
- Fatigue and asthenia (weakness)
- Elevated hepatic transaminases (ALT, AST)
- Musculoskeletal pain (arthralgia, back pain, bone pain)
- Hot flushes
Common
Affects 1 to 10 in 100 patients (1–10%)
- Headache
- Vomiting
- Diarrhea
- Decreased appetite
- Rash, urticaria (hives)
- Peripheral edema (swelling)
- Urinary tract infections
- Elevated bilirubin
- Constipation
- Abdominal pain
- Thrombocytopenia (low platelets) when combined with CDK4/6 inhibitors
Uncommon
Affects 1 to 10 in 1,000 patients (0.1–1%)
- Thromboembolic events (deep vein thrombosis, pulmonary embolism)
- Vaginal hemorrhage
- Hepatitis
- Elevated gamma-glutamyltransferase (GGT)
- Hypersensitivity reactions
Rare
Affects fewer than 1 in 1,000 patients (<0.1%)
- Anaphylaxis
- Angioedema
- Hepatic failure
- Severe injection site necrosis
Injection site reactions are the most characteristic side effect of fulvestrant and are directly related to the intramuscular route of administration. These reactions typically manifest as localized pain, tenderness, or a firm lump at the injection site. Most injection site reactions are mild and resolve spontaneously within a few days. To minimize discomfort, the injection should be administered slowly and gentle pressure (without rubbing) should be applied to the injection site afterward.
Musculoskeletal symptoms such as joint pain, back pain, and bone pain are common during fulvestrant treatment and are likely related to estrogen deprivation. These symptoms are similar to those experienced with aromatase inhibitors and generally reflect the hormonal effects of treatment rather than disease progression. Regular exercise, physiotherapy, and analgesic medications (such as paracetamol or NSAIDs) may help manage these symptoms.
If you experience any severe or persistent side effects, or if you notice symptoms such as sudden shortness of breath, chest pain, severe swelling, yellowing of the skin or eyes, or signs of an allergic reaction, seek immediate medical attention. Always report any new or worsening symptoms to your healthcare team.
How Should You Store Fulvestrant STADA Nordic?
Proper storage of Fulvestrant STADA Nordic is essential to maintain the quality, efficacy, and safety of the medicine. The pre-filled syringes contain a viscous oily solution that must be handled and stored according to specific conditions.
Refrigeration: Store in a refrigerator at 2°C to 8°C (36°F to 46°F). The pre-filled syringes should be stored upright in the original outer carton to protect from light. Do not freeze the product. If the syringe has been frozen, it should not be used, as freezing may damage the syringe components and alter the properties of the solution.
Temporary excursions: For patient convenience, Fulvestrant STADA Nordic may be stored at temperatures up to 30°C (86°F) for a single period of up to 28 days, provided the original carton is retained. If the product is not used within 28 days at room temperature, it should be discarded and not returned to the refrigerator. The date of removal from the refrigerator should be noted on the carton.
Prior to administration: Before injection, remove the pre-filled syringe from the refrigerator and allow it to reach room temperature. This typically takes approximately 15–30 minutes and helps to reduce discomfort during injection of the viscous solution. Do not warm the syringe using any external heat source (such as hot water or a microwave). Inspect the solution visually before use; it should appear as a clear to slightly yellow viscous liquid without visible particles.
Keep this medicine out of the sight and reach of children. Do not use Fulvestrant STADA Nordic after the expiry date stated on the carton and syringe label. Do not dispose of medicines via household waste or wastewater. Return unused syringes to your pharmacy for proper disposal in accordance with local regulations for cytotoxic and antineoplastic agents.
What Does Fulvestrant STADA Nordic Contain?
The active substance in Fulvestrant STADA Nordic is fulvestrant. Each pre-filled syringe contains 250 mg of fulvestrant in 5 mL of solution (50 mg/mL concentration). The standard treatment dose of 500 mg requires two pre-filled syringes per administration.
Excipients (Inactive Ingredients)
- Ethanol (96%): Serves as a co-solvent to maintain fulvestrant in solution within the oily vehicle.
- Benzyl alcohol: Functions as a preservative and co-solvent. Patients with known sensitivity to benzyl alcohol should inform their healthcare provider. Benzyl alcohol may cause allergic reactions in sensitive individuals.
- Benzyl benzoate: Used as a solubilizer and co-solvent to ensure fulvestrant remains dissolved in the formulation.
- Castor oil (refined): The primary vehicle of the injection solution. Castor oil is a viscous oil that provides a depot effect at the injection site, allowing slow and sustained release of fulvestrant into the systemic circulation over weeks.
The castor oil-based formulation is responsible for the slow absorption and long duration of action of fulvestrant following intramuscular injection. The depot formulation releases fulvestrant gradually, maintaining relatively stable plasma levels throughout the dosing interval. This slow-release characteristic supports the once-monthly dosing schedule (after the loading phase).
What the medicine looks like: Fulvestrant STADA Nordic is supplied as a clear to slightly yellow viscous oily solution in Type I glass pre-filled syringes with a luer-lock connection. Each syringe is fitted with a polypropylene plunger rod and a safety needle with a passive needle guard. The product is available in packs containing 2 pre-filled syringes with safety needles (sufficient for one 500 mg dose).
Frequently Asked Questions About Fulvestrant STADA Nordic
Fulvestrant STADA Nordic is used to treat hormone receptor-positive (HR+), locally advanced or metastatic breast cancer in postmenopausal women. It may be used as monotherapy when the disease has progressed after prior antiestrogen therapy, or in combination with CDK4/6 inhibitors (such as palbociclib, ribociclib, or abemaciclib) as first-line or second-line endocrine-based therapy. It is also approved in combination with alpelisib for PIK3CA-mutated HR+/HER2-negative advanced breast cancer. Fulvestrant works by completely blocking and degrading estrogen receptors, preventing estrogen from stimulating cancer cell growth.
Fulvestrant is given as two intramuscular injections, one into each buttock (gluteal muscle), by a healthcare professional. Each injection delivers 250 mg in 5 mL of a viscous oily solution and should be given slowly over 1–2 minutes. Most patients experience some degree of injection site discomfort, which may include pain, tenderness, or a temporary lump at the injection site. Allowing the syringe to reach room temperature before injection and applying gentle pressure afterward can help minimize discomfort. The pain is generally mild and subsides within a few days.
Fulvestrant, tamoxifen, and aromatase inhibitors all target the estrogen pathway in breast cancer but work differently. Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks the estrogen receptor while retaining partial agonist activity in some tissues, which can lead to side effects like endometrial stimulation. Aromatase inhibitors (letrozole, anastrozole, exemestane) reduce estrogen production by blocking the aromatase enzyme but leave the estrogen receptor intact. Fulvestrant is a selective estrogen receptor degrader (SERD) that not only blocks but also degrades the receptor, providing complete elimination of estrogen signaling. This makes fulvestrant effective in patients whose cancer has become resistant to tamoxifen or aromatase inhibitors.
No, Fulvestrant STADA Nordic must not be used during pregnancy. Animal studies have shown reproductive toxicity, including increased fetal loss and abnormalities. Women of childbearing potential must use effective contraception during treatment and for 2 years after the last dose due to the drug's long elimination half-life. If pregnancy is suspected during treatment, the medication should be stopped immediately and the patient should be informed of the potential risk to the fetus. Breastfeeding is also contraindicated during treatment.
Treatment with fulvestrant continues for as long as the patient is benefiting from the medication and the cancer has not progressed. There is no pre-defined maximum duration. Some patients may remain on fulvestrant for many months or even years if the cancer continues to respond. Your oncologist will regularly evaluate the effectiveness of treatment through clinical assessments, blood tests (including tumor markers), and imaging studies (such as CT scans or bone scans). If disease progression occurs, your doctor will discuss alternative treatment options.
If you miss a scheduled fulvestrant injection, contact your healthcare team to arrange the injection as soon as possible. There is no need to restart the loading dose schedule if you are already in the maintenance phase. The next injection should be scheduled approximately one month after the missed dose was administered. If the injection has been delayed by more than two weeks beyond the planned date, consult your oncologist to determine the best timing for resuming your regular schedule. Maintaining consistent monthly injections is important for optimal therapeutic benefit.
References
- European Medicines Agency (EMA). Fulvestrant – Summary of Product Characteristics. Available at: EMA Fulvestrant.
- U.S. Food and Drug Administration (FDA). Faslodex (fulvestrant) – Prescribing Information. AstraZeneca Pharmaceuticals. Revised 2024.
- Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor–Positive Advanced Breast Cancer. J Clin Oncol. 2010;28(30):4594–4600. doi:10.1200/JCO.2010.28.8415.
- Turner NC, Ro J, André F, et al. Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (PALOMA-3). N Engl J Med. 2015;373(3):209–219. doi:10.1056/NEJMoa1505270.
- Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (MONALEESA-3). N Engl J Med. 2020;382(6):514–524. doi:10.1056/NEJMoa1911149.
- Sledge GW Jr, Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy (MONARCH 2). JAMA Oncol. 2020;6(1):116–124. doi:10.1001/jamaoncol.2019.4782.
- André F, Ciruelos E, Rubovszky G, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer (SOLAR-1). N Engl J Med. 2019;380(20):1929–1940. doi:10.1056/NEJMoa1813904.
- European Society for Medical Oncology (ESMO). Clinical Practice Guidelines: Breast Cancer. Updated 2024. Available at: ESMO Breast Cancer Guidelines.
- World Health Organization (WHO). Breast Cancer. Fact Sheet. 2024. Available at: WHO Breast Cancer.
- British National Formulary (BNF). Fulvestrant. National Institute for Health and Care Excellence (NICE). 2025.
About Our Medical Team
All content on iMedic is created and reviewed by qualified medical professionals following international evidence-based guidelines. Our editorial process ensures accuracy, currency, and clinical relevance.
Medical Content Team
Specialists in medical oncology, breast cancer, endocrine therapy, and clinical pharmacology with extensive experience in the management of hormone receptor-positive breast cancer and targeted therapies.
Medical Review Board
Independent panel of board-certified physicians who verify all medical claims against current evidence and international guidelines (WHO, EMA, FDA, ESMO, ASCO).
Editorial Standards
All content follows the GRADE evidence framework and is based on Level 1A evidence from systematic reviews and randomized controlled trials where available.
Independence
iMedic receives no pharmaceutical company funding or sponsorship. All content is editorially independent, ensuring unbiased medical information for patients and caregivers.